Wei Dong Jiang
Founder bei SHANGHAI HENLIUS BIOTECH, INC.
Vermögen: 1 Mio $ am 31.03.2024
Profil
Wei Dong Jiang is the founder of two companies, Henlius Biopharmaceuticals, Inc. and Shanghai Henlius Biotech, Inc., both founded in 2009.
He held the title of Chief Scientific Officer & Vice President at Henlius Biopharmaceuticals, Inc. and Chief Scientific Officer & Senior Vice President at Shanghai Henlius Biotech, Inc. Dr. Jiang has a doctorate degree from the University of Giessen and an undergraduate degree from Zhejiang University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 30.06.2023 | 720 955 ( 0,44% ) | 1 Mio $ | 31.03.2024 |
Aktive Positionen von Wei Dong Jiang
| Unternehmen | Position | Beginn |
|---|---|---|
| SHANGHAI HENLIUS BIOTECH, INC. | Founder | 01.12.2009 |
Ehemalige bekannte Positionen von Wei Dong Jiang
| Unternehmen | Position | Ende |
|---|---|---|
Henlius Biopharmaceuticals, Inc.
 Henlius Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Henlius Biopharmaceuticals, Inc. focuses on development and commercialization of mAb-based therapeutics biosimilars and biobetter for malignant tumors and auto-immune diseases. The company was founded by Scott Liu and Paul Liu in 2009 and is headquartered in Fremont, CA. | Founder | - |
Ausbildung von Wei Dong Jiang
| University of Giessen | Doctorate Degree |
| Zhejiang University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SHANGHAI HENLIUS BIOTECH, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Henlius Biopharmaceuticals, Inc.
Henlius Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Henlius Biopharmaceuticals, Inc. focuses on development and commercialization of mAb-based therapeutics biosimilars and biobetter for malignant tumors and auto-immune diseases. The company was founded by Scott Liu and Paul Liu in 2009 and is headquartered in Fremont, CA. | Health Technology |
